KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis.

Fausto Petrelli, Valentina Bertaglia, Maria Chiara Parati, Karen Borgonovo, Pushpamali De Silva, Andrea Luciani, Silvia Novello, Mario Scartozzi, Leisha A Emens, Cinzia Solinas

Breast 67 8-13

PMID36549170
PMCIDPMC9792383
DOI10.1016/j.breast.2022.12.004
发表日期2022-12-22
摘要

摘要

The current standard of care for resected early-stage triple negative breast cancer (TNBC) patients who did not receive systemic preoperative therapy is adjuvant anthracycline- and taxane-based chemotherapy (CT). A network meta-analysis (NMA) of randomized controlled trials (phase III) enrolling patients with resected stage I-III TNBC comparing adjuvant regimens was performed. Overall survival (OS) and disease-free survival (DFS) data were extracted. A total of 27 phase III clinical trials were selected including 15,242 TNBC patients. This NMA showed an OS benefit from the incorporation of capecitabine into classic anthracycline/taxane-based combinations compared to anthracyclines with or without taxanes alone.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。